EA201990298A1 - Способы и композиции для лечения рака - Google Patents

Способы и композиции для лечения рака

Info

Publication number
EA201990298A1
EA201990298A1 EA201990298A EA201990298A EA201990298A1 EA 201990298 A1 EA201990298 A1 EA 201990298A1 EA 201990298 A EA201990298 A EA 201990298A EA 201990298 A EA201990298 A EA 201990298A EA 201990298 A1 EA201990298 A1 EA 201990298A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
methods
cancer treatment
seq
polypeptide
Prior art date
Application number
EA201990298A
Other languages
English (en)
Inventor
Лаура Соусек
Тони Хаусет Гонсалес
Мари-Эв Болье
Original Assignee
Фундасио Привада Институт Д'Инвестигасио Онколохика Де Валь Хеброн
Институсио Каталана Де Ресерка И Эстудис Авансатс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фундасио Привада Институт Д'Инвестигасио Онколохика Де Валь Хеброн, Институсио Каталана Де Ресерка И Эстудис Авансатс filed Critical Фундасио Привада Институт Д'Инвестигасио Онколохика Де Валь Хеброн
Publication of EA201990298A1 publication Critical patent/EA201990298A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к полипептиду, включающему или состоящему из полипептида с SEQ ID NO: 1, где остаток X в положении 89 в SEQ ID NO: 1 не является цистеином, или функционально эквивалентного варианта указанного полипептида, где остаток X в положении 89 в SEQ ID NO: 1 не является цистеином, и их применению в медицине, в частности, для профилактики и/или лечения рака.
EA201990298A 2016-07-15 2017-07-17 Способы и композиции для лечения рака EA201990298A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382339.6A EP3269734A1 (en) 2016-07-15 2016-07-15 Methods and compositions for the treatment of cancer
PCT/EP2017/067998 WO2018011433A1 (en) 2016-07-15 2017-07-17 Methods and compositions for the treatment of cancer

Publications (1)

Publication Number Publication Date
EA201990298A1 true EA201990298A1 (ru) 2019-06-28

Family

ID=56497695

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990298A EA201990298A1 (ru) 2016-07-15 2017-07-17 Способы и композиции для лечения рака

Country Status (15)

Country Link
US (1) US11427621B2 (ru)
EP (2) EP3269734A1 (ru)
JP (1) JP7090593B2 (ru)
KR (1) KR102232500B1 (ru)
CN (1) CN109563151B (ru)
AU (1) AU2017295071B2 (ru)
BR (1) BR112019000732A2 (ru)
CA (1) CA3029781A1 (ru)
EA (1) EA201990298A1 (ru)
IL (1) IL264176B2 (ru)
MA (1) MA45675A (ru)
MX (1) MX2019000346A (ru)
SG (1) SG11201900021PA (ru)
WO (1) WO2018011433A1 (ru)
ZA (1) ZA201900960B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101729826B1 (ko) * 2015-01-09 2017-05-11 주식회사 동희산업 플라스틱 연료탱크의 제조방법
KR101862239B1 (ko) * 2016-07-07 2018-05-30 주식회사 동희산업 플라스틱 연료탱크의 제조방법
KR101859583B1 (ko) * 2016-07-07 2018-06-27 주식회사 동희산업 플라스틱 연료탱크의 제조방법
EP3269734A1 (en) 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods and compositions for the treatment of cancer
US20210238240A1 (en) * 2018-08-20 2021-08-05 Helix Nanotechnologies, Inc. Methods and compositions for rna expression of myc inhibitors
MX2021011320A (es) * 2019-03-19 2021-12-10 Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron Terapia de combinacion con omomyc y un anticuerpo que se une a pd-1 o a ctla-4 para el tratamiento del cancer.
TWI829893B (zh) * 2019-03-19 2024-01-21 瓦爾希伯倫私人腫瘤研究基金會 診斷肺癌的方法
KR102398339B1 (ko) * 2020-01-09 2022-05-13 이화여자대학교 산학협력단 일산화질소 전달용 융합 펩타이드 및 이의 용도
WO2021208787A1 (zh) * 2020-04-15 2021-10-21 徐荣臻 用于筛选药物的靶标多肽和筛选方法
EP4361633A1 (en) 2022-10-25 2024-05-01 Peptomyc, S.L. Method for predicting response to a cancer treatment

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
EP0654077A4 (en) 1992-07-17 1996-03-13 Ribozyme Pharm Inc PROCESS AND REAGENT FOR THE TREATMENT OF DISEASES IN ANIMALS.
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
CA2228374A1 (en) * 1995-07-31 1997-02-13 Charles R. Vinson Extension of a protein-protein interaction surface to inactivate the function of a cellular protein
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
EP1044021B1 (en) 1998-01-05 2009-09-23 The University of Washington Enhanced transport using membrane disruptive agents
DE60040274D1 (de) 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
WO2013063560A2 (en) 2011-10-27 2013-05-02 New York University INHIBITION OF c-MYC UBIQUITINATION TO PREVENT CANCER INITIATION AND PROGRESSION
EP2801370A1 (en) * 2013-05-07 2014-11-12 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Methods and compositions for the treatment of cancer
EP3269734A1 (en) 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
IL264176A (en) 2019-02-28
JP7090593B2 (ja) 2022-06-24
KR20190032427A (ko) 2019-03-27
KR102232500B1 (ko) 2021-03-26
EP3484913B1 (en) 2024-07-03
ZA201900960B (en) 2020-05-27
WO2018011433A1 (en) 2018-01-18
MA45675A (fr) 2021-04-21
IL264176B1 (en) 2023-03-01
EP3484913A1 (en) 2019-05-22
BR112019000732A2 (pt) 2019-07-30
CN109563151B (zh) 2023-03-07
EP3269734A1 (en) 2018-01-17
JP2019525753A (ja) 2019-09-12
IL264176B2 (en) 2023-07-01
CN109563151A (zh) 2019-04-02
AU2017295071B2 (en) 2022-06-09
CA3029781A1 (en) 2018-01-18
SG11201900021PA (en) 2019-01-30
MX2019000346A (es) 2019-04-01
US20200247857A1 (en) 2020-08-06
US11427621B2 (en) 2022-08-30
AU2017295071A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
EA201990298A1 (ru) Способы и композиции для лечения рака
SV2018005614A (es) Inhibidores peptidicos del receptor de interleucina 23 y uso para tratar enfermedades inflamatorias
PH12015501983A1 (en) Peptides and compositions for treatment of joint damage
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
EA201791775A1 (ru) Цистеиновая протеаза
NZ726448A (en) Improved immunoglobulin variable domains
MD4733B1 (ru) Антитела анти-TIGIT
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
PH12021550122A1 (en) Solubilized apyrases, methods and use
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
SG10201809099PA (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
BR112022001199A2 (pt) Imunoterapia para poliomavírus
BR112019004102A2 (pt) imunoterapia para poliomavírus
BR112018001207A2 (pt) novo peptídeo e uso do mesmo
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease
MX2017007740A (es) Peptido c-terminal de acetilcolinesterasa ciclico en el tratamiento o la prevencion de cancer o metastasis.
MX365952B (es) Composiciones para la prevención y/o el tratamiento de patologías relacionadas con alfa-glucosidasa.
EA201692056A1 (ru) Композиция для личной гигиены
MX2019004179A (es) Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.
MX2019001320A (es) Composicion y uso de un peptido.